Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post–Kidney Transplant: A Case Report

[1]  C. Thongprayoon,et al.  Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis , 2019, Journal of clinical medicine.

[2]  S. Satoh,et al.  Survey of thrombotic microangiopathy within 1 week after kidney transplantation between 2010 and 2015 in Japan , 2018, Clinical and Experimental Nephrology.

[3]  Jon Jin Kim,et al.  Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease , 2018, World journal of transplantation.

[4]  Lily Hoffman-Andrews.  The known unknown: the challenges of genetic variants of uncertain significance in clinical practice , 2017, Journal of law and the biosciences.

[5]  D. Salant,et al.  Thrombotic Microangiopathy: A Multidisciplinary Team Approach. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  G. Remuzzi,et al.  Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[7]  G. Ardissino,et al.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. , 2017, Kidney international.

[8]  J. Hogan,et al.  Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[9]  N. Heyne,et al.  Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome , 2016, Clinical kidney journal.

[10]  N. Goto,et al.  Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. , 2017, Transplantation proceedings.

[11]  R. Alloway,et al.  Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report. , 2017, Transplantation proceedings.

[12]  M. Okumi,et al.  Two cases of kidney transplantation‐associated thrombotic microangiopathy successfully treated with eculizumab , 2016, Nephrology.

[13]  Su-xia Wang,et al.  Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy. , 2016, Journal of the American Society of Nephrology : JASN.

[14]  L. Rostaing,et al.  Belatacept and Long-Term Outcomes in Kidney Transplantation. , 2016, The New England journal of medicine.

[15]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[16]  G. Magnoni,et al.  Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation. , 2014, Transplantation proceedings.

[17]  S. Bhandari,et al.  Case series: hemolytic uremic syndrome--another cause of transplant dysfunction. , 2013, Transplantation proceedings.

[18]  C. Legendre,et al.  Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. , 2013, Transplantation reviews.

[19]  N. Kamar,et al.  Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  V. Frémeaux-Bacchi,et al.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies , 2012, Nature Reviews Nephrology.

[21]  D. Brennan,et al.  Delayed Graft Function in the Kidney Transplant , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  M. Smith,et al.  De novo Thrombotic Microangiopathy in Renal Allograft Biopsies — Role of Antibody-Mediated Rejection , 2011 .

[23]  R. Pelletier,et al.  De novo Thrombotic Microangiopathy in Renal Allograft Biopsies—Role of Antibody‐Mediated Rejection , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  Minnie Sarwal,et al.  Calcineurin Inhibitor Nephrotoxicity , 2012 .

[25]  W. Fridman,et al.  Complement Mutation‐Associated De Novo Thrombotic Microangiopathy Following Kidney Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  L. Agodoa,et al.  Thrombotic microangiopathy after renal transplantation in the United States. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  M. Zand,et al.  De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  L. Truong,et al.  FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. , 1999, Transplantation.

[29]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.